[Chemoendocrine therapy of newly diagnosed advanced prostatic cancer].
From November 1981 to November 1987, 35 patients with newly diagnosed advanced prostatic cancer (6 Stage C cases and 29 Stage D2 cases) were treated by chemoendocrine therapy consisting of orchiectomy, diethylstilbestrol-diphosphate and cisplatin. Objective responses were assessed at 3 months after the start of treatment. Of the 35 patients, 8 had PR (partial response) and 27 was objective stable by NPCP criteria. Objective progression was not seen. In analysis of long-term results, the 3-year and 5-year survival rate for total cases were 75.8% and 60.7%, respectively. For Stage C cases, the 3-year and 5-year survival rates were 100% and 100%; for Stage D2 cases, they were 72.2% and 54.2%, respectively. Relapse was seen in 7 (24.1%) of the 29 Stage D2 cases. All of these 7 patients had poorly differentiated adenocarcinoma and most of them had more than 10 bone metastases. As for side-effects, gastroenteric symptoms (nausea and vomiting), anemia and slight liver dysfunction were seen. These results suggest that the chemoendocrine therapy is an effective treatment in newly diagnosed cases of advanced prostatic cancer.
Numasawa
K
K
Kubota
Y
Y
Suzuki
H
H
Kakizaki
H
H
Takamizawa
A
A
Saito
M
M
Suzuki
K
K
Kato
H
H
Hirano
J
J
Hirano
K
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D012074:Remission Induction
D004054:Diethylstilbestrol; C004955:fosfestrol; D002945:Cisplatin